Related Experiment Video
Updated: Aug 8, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Update on intracerebral haemorrhage
1Centro de Estudos Egas Moniz, Hospital de Santa Maria, Lisboa 1649-035, Portugal. jmferro@fm.ul.pt
Insights
Intracerebral haemorrhage (ICH) is a severe stroke type with high mortality. While some treatments show promise, surgery offers no benefit over conservative care for acute ICH.
Area of Science:
- Neurology
- Neurosurgery
- Cardiovascular Medicine
Background:
- Intracerebral haemorrhage (ICH) is a critical cerebrovascular disease with higher mortality than ischemic stroke.
- Hypertension is a primary risk factor, increasing ICH risk fourfold.
- MRI markers like microbleeds and white matter changes indicate ICH risk.
Purpose of the Study:
- To review the pathophysiology and current treatment strategies for intracerebral haemorrhage.
- To evaluate the efficacy and safety of interventions aimed at limiting haematoma growth and improving patient outcomes.
Main Methods:
- Review of pathophysiological phases of ICH, including haematoma formation, enlargement, and oedema.
- Analysis of randomized clinical trials (RCTs) investigating treatments such as recombinant activated Factor VIIa (rFVIIa) and surgical interventions.
- Consideration of adjunctive therapies like ventricular drainage with thrombolytics for intraventricular bleeding.
Main Results:
- rFVIIa limited haematoma growth and improved outcomes but increased thromboembolic complications.
- Surgical intervention for acute ICH has not demonstrated benefits over conservative management in large trials and meta-analyses.
- Ventricular drainage with thrombolytics may benefit patients with intraventricular bleeding.
Conclusions:
- ICH is a devastating condition with poor functional independence rates.
- Current evidence does not support surgical intervention for acute ICH.
- Further research into effective treatments for ICH, particularly concerning haematoma expansion and secondary injury, is warranted.
Abstract:
Intracerebral haemorrhage (ICH) is a common and serious disease. About 1 to 2 out of 10 patients with stroke have an ICH. The mortality of ICH is higher than that of ischaemic stroke. Only 31% are functionally independent at 3 months. Only 38% of the patients survive the 1(st) year. The cost of ICH is high. Hypertension is the major risk factor, increasing the risk of ICH about 4x. Up to half of hypertensive patients who suffer a ICH are either unaware of their hypertension, non-compliant with the medication or fail to control periodically their blood pressure levels Microbleeds and white matter changes are MRI markers of the risk of ICH. ICH has 3 main pathophysiological phases: arterial rupture and haematoma formation, haematoma enlargement and peri-haematoma oedema. Up to 40% of the haematomas grow in the first hours post-rupture. ICH growth is associated with early clinical deterioration. Two randomised clinical trials (RCTs) demonstrated that treatment with rFVIIa limited haematoma growth and improved outcome, but was associated with a increase in thromboembolic complications. Ventricular drainage with thrombolytics might improve outcome for patients with intraventricular bleeding. A large RCT and meta-analysis failed to show a benefit of surgery over conservative treatment in acute ICH.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Increased Intracranial Pressure l: Introduction
Cerebral Edema ll: Pathophysiology
